文档介绍：Cheson et al, J Clin Oncol 17:1244, 1999
In 1999, an International Working Group (IWG) of clinicians, radiologists, and pathologists with expertise in the evaluation and management of patients with Lymphoma published guidelines for response assessment and outcomes measurement.
Response Criteria for Lymphoma
Reappearance
New or increased
New or increased
Enlarging liver/spleen; new sites
Relapse/
progression
Irrelevant
≥50% decrease
≥ 50% decrease
Decrease in liver/spleen
Irrelevant
≥50% decrease
≥50% decrease
Normal
Positive
Normal
Normal
Normal
PR
Normal or indeterminate
> 75% decrease
Normal
Normal
Indeterminate
Normal
Normal
Normal
CRu
Normal
Normal
Normal
Normal
CR
Bone Marrow
Lymph Node Masses
Lymph Nodes
Physical Examination
Response Category
Definitions of End Points for Clinical Trials
Death
Death related to NHL
All patients
Cause-specific death
Entry onto trial
Time when new treatment is needed
All patients
Time to next treatment
First documentation of response
Time to relapse or progression
CR, CRu, PR
Response duration
First documentation of response
Time to relapse
CR, CRu
Disease-free survival
Entry onto trial
Disease progression or death from NHL
All patients
Progression-free survival
Entry onto trial
Failure or death from any cause
CR, CRu, PR
Event-free survival
Entry onto trial
Death from any cause
All patients
Overall survival
Point of Measurement
Definition
Response Category
End Point
Standardized response criteria provide uniform end points for clinical trials:
Allowing for comparisons among studies
Facilitating the identification of more
effective therapies
The widely used IWG criteria for response assessment of lymphoma are based predominantly on CT.It became clear that the International Working Group criteria warranted revision, because of identified limitations and the increased use of :
[18F]